Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

NCT01972750 is registered in ClinicalTrials.gov with PD Dr. Martin Glas as lead sponsor.

NCT NCT01972750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01972750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
Lead sponsor
PD Dr. Martin Glas
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2013
Completion date
November 30, 2016
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first or second recurrence of glioblastoma